Clinical Trials

    Showing 1 - 6 of 6 Maen Abdelrahim

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.... Read more >

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child... Read more >

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evalu... Read more >

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Beatriz Efron

    Phone: 713.363.8890

    This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for dise... Read more >

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Elsie Rizk

    Phone: 713.441.2557

    Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolizatio... Read more >

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Elsie Rizk

    Phone: 713.441.2557

    We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcomes, an... Read more >